Blog
RSS FeedPosted by Michael Wonder on 25 Apr 2018
Generic drug companies to face first charges in U.S. probe
25 April 2018 - Mylan headquarters searched by law enforcement in 2016. ...
Posted by Michael Wonder on 28 Mar 2018
In battle to cut drug prices, outcome-based pricing carries big risks for biopharma
28 March 2018 - In a provocative piece entitled “Trump’s Health Secretary Wants To Transform Healthcare. Can He?”, fellow Forbes contributor, ...
Posted by Michael Wonder on 19 Mar 2018
Workshop on paediatric regulation – stakeholders to discuss how to boost development of medicines for children
19 March 2018 - Event to be broadcast live on 20 March. ...
Posted by Michael Wonder on 28 Feb 2018
Europe follows FDA with plans to help early Alzheimer's drugs
28 February 2018 - European regulators are following in the footsteps of the U.S. Food and Drug Administration with plans ...
Posted by Michael Wonder on 28 Feb 2018
Drug makers lobby for antibiotic incentives in pandemic preparedness bill
27 February 2018 - A big legislative package due for renewal later this year could include hundreds of millions of ...
Posted by Michael Wonder on 22 Feb 2018
The CEO of Merck on race, leadership, and high drug prices
19 February 2018 - Kenneth Frazier, the CEO of MSD, discusses his upbringing and how it influences his leadership as chief ...
Posted by Michael Wonder on 21 Feb 2018
Industry's experiences with the scientific advice offered by the Federal Joint Committee within the early benefit assessment of pharmaceuticals in Germany
19 February 2018 - Optional scientific advice for the early benefit assessment of pharmaceuticals is offered by the German decision maker, ...
Posted by Michael Wonder on 13 Feb 2018
Statement from FDA Commissioner Scott Gottlieb on Administration’s request for new FDA funding to promote innovation and broaden patient access through competition
13 February 2018 - Additional resources will help advance initiatives to support novel medical technology and public health priorities such as ...
Posted by Michael Wonder on 13 Feb 2018
Pharma gets the worst of both drug pricing worlds
14 February 2018 - Growth is slowing dramatically, but the political pressure isn't. ...
Posted by Michael Wonder on 06 Feb 2018
AusBiotech says plan to disadvantage life sciences innovation
6 February 2018 - Response to Innovation and Science Australia 2030 plan. ...
Posted by Michael Wonder on 05 Feb 2018
Standard deviation and standard error: interpretation, usage and reporting
5 February 2018 - Standard deviations and standard errors are reported routinely in statistical analyses, but the distinction between them is ...
Posted by Michael Wonder on 31 Jan 2018
How to better apply the paediatric legislation to boost development of medicines for children
31 January 2018 - EMA and European Commission invite stakeholders to register for joint workshop and support development of an ...
Posted by Michael Wonder on 31 Jan 2018
Industry needs clarity to invest in Australia
31 January 2018 - Medicines Australia welcomes the release of the 2030 plan by Innovation and Science Australia but seeks ...
Posted by Michael Wonder on 29 Jan 2018
Medicines Australia welcomes LSDP review outcomes
28 January 2018 - Medicines Australia welcomes the Government’s announcement of an outcome from the post-market review of the Life ...
Posted by Michael Wonder on 24 Jan 2018
PhRMA launches new consumer-facing Let's Talk About Cost website
24 January 2018 - Today, as part of the Let's Talk About Cost campaign, PhRMA launched LetsTalkAboutCost.org, a national consumer-facing ...